Can the battle against tuberculosis gain from epigenetic research?

Trends in Microbiology

Volumn 20, Issue 5, 2012, Pages 220-226

  Esterhuyse, Maria M ^a   Linhart, Heinz G ^b   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biomarkers; DNA methylation; Epigenetics; Tuberculosis

Indexed keywords

DNA METHYLATION; EPIGENETICS; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INFECTION; LATENT TUBERCULOSIS; PANDEMIC; PLASTICITY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUBERCULOSIS;

ANIMALS; BIOMEDICAL RESEARCH; EPIGENOMICS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84860581386     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.03.002     Document Type: Review

References (77)

1. Wolff C.F. Theoria Generationis 1759, Halle.
2. Waddington C.H. Preliminary notes on the development of the wings in normal and mutant strains of Drosophila. Proc. Natl. Acad. Sci. U.S.A. 1939, 25:299-307.
3. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
4. Holliday R. The inheritance of epigenetic defects. Science 1987, 238:163-170.
5. Bagot R.C., Meaney M.J. Epigenetics and the biological basis of gene×environment interactions. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49:752-771.
6. Fernandez-Morera J.L., et al. Epigenetic regulation of the immune system in health and disease. Tissue Antigens 2010, 76:431-439.
7. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33:245-254.
8. Cooper A. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 2009, 27:393-422.
9. Walzl G., et al. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 2011, 11:343-354.
10. Parida S.K., Kaufmann S.H.E. The quest for biomarkers in tuberculosis. Drug Discov. Today 2010, 15:148-157.
11. Vannberg F.O., et al. Human genetic susceptibility to intracellular pathogens. Immunol. Rev. 2011, 240:105-116.
12. Alcaïs A., et al. Human genetics of infectious diseases: between proof of principle and paradigm. J. Clin. Investig. 2009, 119:2506-2514.
13. Lawn S.D., Zumla A.I. Tuberculosis. The Lancet 2011, 378:57-72.
14. Qu H.Q., et al. Knowledge gaining by human genetic studies on tuberculosis susceptibility. J. Hum. Genet. 2011, 56:177-182.
15. Thye T., et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nat. Genet. 2010, 42:739-741.
16. Su R.-C., et al. Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood 2011, 117:2649-2657.
17. Reiner S.L. Epigenetic control in the immune response. Hum. Mol. Genet. 2005, 14:R41-R46.
18. Wilson C.B., et al. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 2009, 9:91.
19. Bayarsaihan D. Epigenetic mechanisms in inflammation. J. Dent. Res. 2011, 90:9-17.
20. Minárovits J. Microbe-induced epigenetic alterations in host cells: the coming era of patho-epigenetics of microbial infections. Acta Microbiol. Immunol. Hung. 2009, 56:1-19.
21. Paschos K., Allday M.J. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 2010, 18:439-447.
22. Zhu J., et al. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 2010, 28:445-489.
23. Gamper C.J., et al. Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J. Immunol. 2009, 183:2267-2276.
24. Zou Y.R., et al. Epigenetic silencing of CD4 in T cells committed to the cytotoxic lineage. Nat. Genet. 2001, 29:332-336.
25. Huehn J., et al. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat. Rev. Immunol. 2009, 9:83-89.
26. Wright K.L., Ting J.P.Y. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 2006, 27:405-412.
27. Accolla R.S., et al. The MHC class II transactivator: prey and hunter in infectious diseases. Trends Immunol. 2001, 22:560-563.
28. Morris A.C., et al. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J. Immunol. 2000, 164:4143-4149.
29. Zika E., et al. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-γ-inducible MHC-II gene expression. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16321-16326.
30. Jabrane-Ferrat N., et al. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol. Cell. Biol. 2002, 22:5616-5625.
31. Galli S.J., et al. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 2011, 12:1035-1044.
32. Satoh T., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 2010, 11:936-944.
33. Ishii M., et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009, 114:3244-3254.
34. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
35. Cui H., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299:1753-1755.
36. Maekita T., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 2006, 12:989-995.
37. Park S.-Y., et al. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J. Pathol. 2009, 219:410-416.
38. Compare D., et al. Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J. Clin. Pathol. 2011, 64:677-682.
39. Giordanengo V., et al. Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells. FASEB J. 2004, 18:1961-1963.
40. Andraos C., et al. Vitamin D receptor gene methylation is associated with ethnicity, tuberculosis, and TaqI polymorphism. Hum. Immunol. 2011, 72:262-268.
41. Mulero-Navarro S., Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 2008, 68:1-11.
42. Lind G., et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol. Cancer 2011, 10:85.
43. Verma M., et al. Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol. Diagn. Ther. 2006, 10:1-15.
44. Ebert M.P.A., et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med. 2012, 366:44-53.
45. Bocker M.T., et al. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 2011, 117:e182-e189.
46. Meissner A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-770.
47. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
48. Waddington C. The epigenotype. Endeavour 1942, 1:18-20.
49. Murrell A., et al. From genome to epigenome. Hum. Mol. Genet. 2005, 14:R3-R10.
50. Edwards T.M., Myers J.P. Environmental exposures and gene regulation in disease etiology. Environ. Health Perspect. 2007, 115:1264.
51. El-Osta A. Understanding the consequences of epigenetic mechanisms and its effects on transcription in health and disease. Cancer Biol. Ther. 2004, 3:816-818.
52. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell Biol. 2009, 41:87-95.
53. Morgan D., Whitelaw E. The case for transgenerational epigenetic inheritance in humans. Mamm. Genome 2008, 19:394-397.
54. Bernstein B.E., et al. The mammalian epigenome. Cell 2007, 128:669-681.
55. Cedar H., Bergman Y. Epigenetics of haematopoietic cell development. Nat. Rev. Immunol. 2011, 11:478-488.
56. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10:805-811.
57. Waddington C.H. Canalization of development and the inheritance of acquired characters. Nature 1942, 150:563-565.
58. Ferguson-Smith A.C., et al. Epigenomics 2009, Springer.
59. Yang X., et al. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 2010, 31:536-546.
60. Dwivedi R.S., et al. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int. 2011, 79:23-32.
61. Gibney E.R., Nolan C.M. Epigenetics and gene expression. Heredity 2010, 105:4-13.
62. Wang Y., et al. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin. Genet. 2008, 74:307-315.
63. Valeri N., et al. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm. Genome 2009, 20:573-580.
64. Buckley N.J., et al. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 2010, 39:28-39.
65. Chodavarapu R.K., et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010, 466:388-392.
66. Vaissišre T., et al. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 2008, 659:40-48.
67. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10:295-304.
68. Dorhoi A., et al. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol. Rev. 2011, 240:235-251.
69. Möller M., et al. Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol. Med. Microbiol. 2010, 58:3-26.
70. Hoal E.G. Human genetic susceptibility to tuberculosis and other mycobacterial diseases. IUBMB Life 2002, 53:225-229.
71. Stein C.M., Baker A.R. Tuberculosis as a complex trait: impact of genetic epidemiological study design. Mamm. Genome 2011, 22:91-99.
72. Casanova J.-L., et al. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 2011, 29:447-491.
73. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
74. Ficz G., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473:398-402.
75. Nguyen A., et al. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 2010, 24:3036-3051.
76. Kirillov A. A role for nuclear NF-κB in B-cell-specific demethylation of the Igκ locus. Nat. Genet. 1996, 13:435-441.
77. Ji H., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467:338-342.